

Table SI. Participant demographics, skin cancer history and transplant history by transplant organ group

Baseline characteristics	Kidney (n = 281) n (%)	Liver (n = 195) n (%)	p-value ^a
Age			0.009
<50 years	91 (33)	39 (20)	
50–59 years	79 (28)	71 (36)	
≥60 years	111 (40)	85 (44)	
Sex			0.48
Female	104 (37)	66 (34)	
Male	177 (63)	129 (66)	
Born in Australia			0.38
Yes	205 (73)	135 (69)	
No	76 (27)	60 (31)	
Completed education ^b			0.17
Grade 12 or less	146 (56)	99 (55)	
Trade/diploma	63 (24)	56 (31)	
University/college	51 (20)	26 (14)	
Skin colour			0.081
Olive/medium	103 (37)	87 (45)	
Fair	178 (63)	108 (55)	
Lifetime painful sunburns ^b			0.72
up to 5 times	159 (61)	114 (63)	
>5 times	102 (39)	68 (37)	
Time since first transplant			0.67
1–5 years	87 (31)	64 (33)	
>5 years	194 (69)	131 (67)	
KC at baseline			0.47
No	214 (76)	154 (79)	
Yes	67 (24)	41 (21)	
Skin cancers excised/treated ^b			0.011
Nil	80 (31)	77 (42)	
≤5	108 (41)	63 (35)	
6–10	26 (10)	24 (13)	
>10	47 (18)	18 (10)	
Frequency of skin checks over 5 years ^b			0.002
Up to once a year	154 (59)	133 (73)	
>5 (> once a year)	107 (41)	49 (27)	
Immunosuppression ^c			
Monotherapy	4 (1)	101 (52)	–
Antimetabolites	0 (0)	2 (2)	
Calcineurin inhibitors	4 (100)	99 (98)	
Dual therapy	42 (15)	67 (34)	–
Calcineurin inhibitor + corticosteroid	18 (43)	41 (61)	
Azathioprine + corticosteroid	4 (10)	8 (12)	
MMF + corticosteroid	2 (5)	1 (2)	
mTOR inhibitor + corticosteroid	0 (0)	2 (3)	
Calcineurin inhibitor + azathioprine	5 (12)	12 (18)	
Calcineurin inhibitor + MMF	9 (21)	3 (5)	
Other	4 (10)	0 (0)	
Triple therapy	232 (83)	27 (14)	–
Calcineurin inhibitor + corticosteroid + MMF	178 (77)	0 (0)	
Calcineurin inhibitor + corticosteroid + Azathioprine	29 (13)	25 (93)	
Calcineurin inhibitor + corticosteroid + mTOR inhibitor	4 (2)	0 (0)	
MMF + corticosteroid + mTOR inhibitor	16 (7)	1 (4)	
Other	5 (2)	1 (4)	
Quadruple therapy	3 (1)	0 (0)	–
Calcium inhibitor + Azathioprine + MMF + corticosteroid	3 (100)	0 (0)	

^ap-value compares across kidney and liver high-risk populations. ^bSome participants did not provide this information.

^cNumbers in parentheses for specific types of medications refer to percentage of category of immunosuppression (mono/dual/triple/quadruple).

MMF: mycophenolate mofetil; KC: keratinocyte cancers.